Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer

BACKGROUND: Platinum doublets are standard first-line treatment for stage IV non-small cell lung cancer (NSCLC) without targetable driver mutations. Oxaliplatin is more potent than cisplatin, requiring fewer DNA adducts to provide equivalent cytotoxicity. The objective of this study was to evaluate...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Thorac Cancer
Autors principals: Ban, Heejung, Kim, Kyu-Sik, Oh, In-Jae, Yoon, Seong-Hoon, Lee, Boram, Yu, Jinyeong, Kim, Sunmin, Lee, Ho-Sung, Shin, Hong-Joon, Park, Cheol-Kyu, Kwon, Yong-Soo, Kim, Yu-Il, Lim, Sung-Chul, Kim, Young-Chul
Format: Artigo
Idioma:Inglês
Publicat: BlackWell Publishing Ltd 2014
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4704330/
https://ncbi.nlm.nih.gov/pubmed/26767047
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12123
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars